-
-
[1] Marx SJ. Hyperparathyroid and hypoparathyroid disorders[J]. N Engl J Med, 2000, 343:1863-1875. http://onlinelibrary.wiley.com/resolve/reference/PMED?id=11117980 [2] Hou R, Manwaring LP, Moley JF, et al. A novel missense mutation in the MEN1 gene in a patient with multiple endocrine neoplasia type 1[J]. Endocr Pract, 2011, 17:e63-e67. doi: 10.4158/ep10291.cr [3] Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1(MEN1):analysis of 1336 mutations reported in the first decade following identification of the gene[J]. Hum Mutat, 2008, 29:22-32. doi: 10.1002/humu.20605 [4] Dreijerink KM, Hoppener JW, Timmers HM, et al. Mechanisms of disease:multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation[J]. Nat Clin Pract Endocrinol Metab, 2006, 2:562-570. http://www.ncbi.nlm.nih.gov/pubmed/17024155 [5] Davenport C, Agha A. The role of menin in parathyroid tumorigenesis[J]. Adv Exp Med Biol, 2009, 668:79-86. http://www.ncbi.nlm.nih.gov/pubmed/20175455 [6] Yu D, Nagamura Y, Shimazu S, et al. Caspase 8 and menin expressions are not correlated in human parathyroid tumors[J]. Endocr J, 2010, 57:825-832. http://new.med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_JJ0216489620 [7] Buchwald PC, Akerstrom G, Westin G. Reduced p18INK4c, p21CIP1/WAF1 and p27KIP1 mRNA levels in tumours of primary and secondary hyperparathyroidism[J]. Clin Endocrinol (Oxf), 2004, 60:389-393. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1111/j.1365-2265.2004.01995.x [8] Nagamura Y, Yamazaki M, Shimazu S, et al. A novel splice site mutation of the MEN1 gene identified in a patient with primary hyperparathyroidism[J]. Endocr J, 2012, 59:523-530. http://www.zhangqiaokeyan.com/academic-journal-foreign_other_thesis/020419266529.html [9] Busygina V, Kottemann MC, Scott KL, et al. Multiple endocrine neoplasia type 1 interacts with forkhead transcription factor CHES1 in DNA damage response[J]. Cancer Res, 2006, 66:8397-8403. http://europepmc.org/abstract/MED/16951149 [10] Schnepp RW, Hou Z, Wang H, et al. Functional interaction between tumor suppressor menin and activator of S-phase kinase[J]. Cancer Res, 2004, 64:6791-6796. http://www.ncbi.nlm.nih.gov/pubmed/15374998 [11] Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome[J]. Nat Genet, 2002, 32:676-680. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=8027ab0f46a3268b3512048a835a4edb [12] Rodgers SE, Perrier ND. Parathyroid carcinoma[J]. Curr Opin Oncol, 2006, 18:16-22. http://www.ncbi.nlm.nih.gov/pubmed/16357559 [13] Lin L, Zhang JH, Panicker LM, et al. The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene[J]. Proc Natl Acad Sci USA, 2008, 105:17420-17425. http://www.pnas.org/content/105/45/17420.abstract [14] Lin L, Czapiga M, Nini L, et al. Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function[J]. Mol Cancer Res, 2007, 5:183-193. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=751b04463f3c1ed9e0e3d94a8478e05a [15] Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, et al. The parafibromin tumor suppressor protein is part of a human Paf1 complex[J]. Mol Cell Biol, 2005, 25:612-620. http://europepmc.org/articles/PMC543415/ [16] Westin G, Bjorklund P, Akerstrom G. Molecular genetics of parathyroid disease[J]. World J Surg, 2009, 33:2224-2233. http://www.diva-portal.org/smash/record.jsf?pid=diva2:924042 [17] Panicker LM, Zhang JH, Dagur PK, et al. Defective nucleolar localization and dominant interfering properties of a parafibromin l95p missense mutant causing the hyperparathyroidism-jaw tumor syndrome[J]. Endocr Relat Cancer, 2010, 17:513-524. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=9d4c345182a5e44f5bf9434c6fab6a77 [18] Lim S, Elston MS, Gill AJ, et al. Metastatic parathyroid carcinoma initially misdiagnosed as parathyroid adenoma:the role of parafibromin in increasing diagnostic accuracy[J]. Intern Med J, 2011, 41:695-699. doi: 10.1111/j.1445-5994.2011.02545.x [19] Juhlin CC, Haglund F, Obara T, et al. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours[J]. Virchows Arch, 2011, 459:47-53. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=06d83b16819f886f23f712b711571ed6 [20] Juhlin CC, Villablanca A, Sandelin K, et al. Parafibromin immunoreactivity:its use as an additional diagnostic marker for parathyroid tumor classification[J]. Endocr Relat Cancer, 2007, 14:501-512. http://www.ncbi.nlm.nih.gov/pubmed/17639063 [21] Howell VM, Gill A, Clarkson A, et al. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma[J]. J Clin Endocrinol Metab, 2009, 94:434-441. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=f3e833a5beec2d29880dd8a3ffde4a9f [22] Farnebo F, Enberg U, Grimelius L, et al. Tumor-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism[J]. J Clin Endocrinol Metab, 1997, 82:3481-3486. http://www.ncbi.nlm.nih.gov/pubmed/9329389 [23] Mallya SM, Gallagher JJ, Wild YK, et al. Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism[J]. Mol Endocrinol, 2005, 19:2603-2609. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=1c577497d2c58ca1dc5cc2442f55d259 [24] Ward BK, Magno AL, Walsh JP, et al. The role of the calcium-sensing receptor in human disease[J]. Clin Biochem, 2012, 45:943-953. https://www.ncbi.nlm.nih.gov/pubmed/22503956 [25] Cozzolino M, Mazzaferro S, Messa P. New insights into the role of calcium-sensing receptor activation[J]. J Nephrol, 2011, 24:S38-S41. http://www.ncbi.nlm.nih.gov/pubmed/21623581 [26] Falchetti A, Gozzini A, Terranegra A, et al. A novel germline inactivating mutation in the CASR gene in an Italian kindred affected by familial hypocalciuric hypercalcemia[J]. Eur J Endocrinol, 2012, 166:933-940. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=f60a539ee3d4adadc6ca2816a4bf4500 [27] Canaff L, Zhou X, Mosesova I, et al. Glial cells missing-2(GCM2) transactivates the calcium-sensing receptor gene:effect of a dominant-negative GCM2 mutant associated with autosomal dominant hypoparathyroidism[J]. Hum Mutat, 2009, 30:85-92. https://www.researchgate.net/publication/23180093_Glial_Cells_Missing-2_GCM2_Transactivates_the_Calcium-Sensing_Receptor_Gene_Effect_of_a_Dominant-Negative_GCM2_Mutant_Associated_With_Autosomal_Dominant_Hypoparathyroidism [28] Motokura T, Bloom T, Kim HG, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene[J]. Nature, 1991, 350:512-515. http://carcin.oxfordjournals.org/external-ref?access_num=10.1038/350512a0&link_type=DOI [29] Erickson LA, Jalal SM, Harwood A, et al. Analysis of parathyroid neoplasms by interphase fluorescence in situ hybridization[J]. Am J Surg Pathol, 2004, 28:578-584. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=WK_LWW201705250085142 [30] Yi Y, Nowak NJ, Pacchia AL, et al. Chromosome 11 genomic changes in parathyroid adenoma and hyperplasia:array cgh, fish, and tissue microarrays[J]. Genes Chromosomes Cancer, 2008, 47:639-648. http://www.ncbi.nlm.nih.gov/pubmed/18398822 [31] Westin G, Bjorklund P, Akerstrom G. Molecular genetics of parathyroid disease[J]. World J Surg, 2009, 33:2224-2233. http://www.diva-portal.org/smash/record.jsf?pid=diva2:924042 [32] Cetani F, Pardi E, Viacava P, et al. A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer[J]. Clin Endocrinol (Oxf), 2004, 60:99-106. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1111/j.1365-2265.2004.01954.x [33] Imanishi Y, Hosokawa Y, Yoshimoto K, et al. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice[J]. J Clin Invest, 2001, 107:1093-1102. http://ndt.oxfordjournals.org/external-ref?access_num=10.1172/JCI10523&link_type=DOI [34] Erickson LA, Jin L, Wollan PC, et al. Expression of p27KIP1 and Ki-67 in benign and malignant thyroid tumors[J]. Mod Pathol, 1998, 11:169-174. http://www.ncbi.nlm.nih.gov/pubmed/9731735 [35] DeLellis RA. Parathyroid carcinoma:an overview[J]. Adv Anat Pathol, 2005, 12:53-61. http://www.ncbi.nlm.nih.gov/pubmed/15731573 [36] Fernandez-Ranvier GG, Khanafshar E, Tacha D, et al. Defining a molecular phenotype for benign and malignant parathyroid tumors[J]. Cancer, 2009, 115:334-344. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1002/cncr.24037 [37] Chen CH, Chuang SM, Yang MF, et al. A novel function of YWHAZ/β-catenin axis in promoting epithelial-mesenchymal transition and lung cancer metastasis[J]. Mol Cancer Res, 2012, 10:1319-1331. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=aaf44e93c0ce12688cd94e136debfa37 [38] Morrison DK. The 14-3-3 proteins:integrators of diverse signaling cues that impact cell fate and cancer development[J]. Trends Cell Biol, 2009, 19:16-23. http://onlinelibrary.wiley.com/resolve/reference/PMED?id=19027299 [39] Bayrhuber M, Meins T, Habeck M, et al. Structure of the human voltage-dependent anion channel[J]. Proc Natl Acad Sci U S A, 2008, 105:15370-15375. http://www.pnas.org/content/105/40/15370.abstract [40] Giusti L, Cetani F, Ciregia F, et al. A proteomic approach to study parathyroid glands[J]. Mol Biosyst, 2011, 7:687-699. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=f88f4a86016d02278851bbbf2e6ae09e
点击查看大图
计量
- 文章访问数: 249
- HTML全文浏览量: 75
- PDF下载量: 1
- 被引次数: 0